A Legacy of Innovation. A Vision for the Future.
At ReiThera, we help biotech innovators transform breakthrough science into advanced therapies. Through integrated development, analytical, regulatory, and GMP manufacturing services, we support programs from early research to clinical and commercial readiness, combining decades of expertise in viral vectors, genetic vaccines, and advanced therapeutics.
Decades of Collective Experience
Our strength comes from the people behind the science. Bringing together decades of experience in biotechnology, pharmaceutical development, and GMP manufacturing, our multidisciplinary team helps innovators navigate the complex path from breakthrough discovery to clinical reality.
Proprietary Platform
At ReiThera, we develop and manufacture advanced genetic vaccines and biotherapeutics using proprietary platform technologies designed for safety, scalability, and clinical impact.
MVA
A Trusted Technology for Genetic Vaccines
GRAD
A Next-Generation Adenoviral Vector for Powerful Immune Responses
REICELL AAV
A Scalable HEK293 Line for AAV Vector Manufacturing
Capabilities
From early-stage vector design to clinical-grade production, our end-to-end capabilities ensure a seamless, scalable path to market for genetic vaccines and advanced therapies.
Technology Development
Driving Innovation in Viral and Non-Viral Vector Platforms
process development
Optimizing Bioproduction for Scalable Viral Vector Manufacturing
gmp manufacturing
State-of-the-Art Infrastructure for Viral Vector Production
Quality System
Built-in Quality. Proven Compliance. Trusted Delivery.
Analytics
Data-Driven Development. Built for Viral Vectors.
Our science
The future of medicine is being delivered. Gene therapies, genetic vaccines, and next-generation immunotherapies are redefining how we prevent and treat disease. Behind every breakthrough is a delivery technology capable of bringing innovative science where it needs to go.
At ReiThera, viral vectors are at the heart of what we do. We combine vector engineering, process development, analytical expertise, regulatory support, and GMP manufacturing to help transform scientific innovation into real therapeutic solutions.
Our technology portfolio spans adenoviral vectors, Adeno-Associated Viruses (AAV), and Modified Vaccinia Ankara (MVA), supported by proprietary platforms, scalable manufacturing processes, and deep scientific expertise. From early discovery to clinical and commercial readiness, we help our partners unlock the full potential of viral vector technologies and bring the next generation of advanced therapies closer to patients. Because great science deserves the right delivery system.
2,000
Lt
Bioreactor Capacity
3,470
m²
Manufacturing Site
6
Independent GMP Suites
3,500
Vials per Batch Fill-Finish Capacity
3,000
Lt
Parallel GMP Manufacturing Campaigns
Why choose us
ReiThera is a leading innovator in genetic vaccines and advanced therapies, combining decades of scientific expertise with cutting-edge GMP manufacturing. Our team brings together deep experience in viral vector engineering, immunology, and clinical development, with a proven track record in addressing global health challenges.
We offer end-to-end support—from vector design and preclinical research to clinical-grade manufacturing—specializing in adenoviral, AAV, and MVA platforms. Our state-of-the-art facility meets the highest international GMP standards, enabling scalable, aseptic production of viral vectors and ATMPs.
With a strong commitment to quality, flexibility, and scientific rigor, ReiThera is your trusted partner for turning groundbreaking science into transformative therapies.
Our facility
ReiThera’s GMP facility is a cutting-edge site for viral vector and biologics manufacturing. It features large-scale bioreactors, advanced cleanrooms, and aseptic filling capabilities, supporting end-to-end development and production under the highest quality standards for both clinical and research applications.
